What Aurora Diagnostics Holdings, LLC does

Aurora Diagnostics Holdings, LLC was founded in 2006 as a diagnostic pathology company and was acquired by Sonic Healthcare USA in 2019, after which it was rebranded as the Sonic Healthcare USA Anatomic Pathology Division. The company no longer operates as a standalone entity but continues as a wholly-owned division providing anatomic pathology and diagnostic laboratory services across the United States through a federated network of regional laboratories and pathology practices.

The company delivers a comprehensive diagnostic testing portfolio centered on anatomic pathology, molecular diagnostics, dermatopathology, hospital services, and companion diagnostics. Its product portfolio includes the AuraSeq Comprehensive Panel (a 500-gene NGS assay for cancer-related alterations), ThyroSeq for thyroid cancer molecular testing, FDA-approved companion diagnostics (FOLR1, MMR RxDx Panel, and indication-specific PD-L1 stains), women's health diagnostics under the AVID brand (Complete, Screen, Auto-Reflex), and COVID-19/flu multiplex testing. The technical stack includes the PathologyWatch digital pathology platform powered by 'dot.' AI technology for dermatopathology, the iMorpheus clinical decision support and pattern recognition platform, and SonicMyAccess for patient result access. The company maintains 380+ EHR vendor integrations with 25,000+ active EHR interfaces.

The business operates on a transaction-fee revenue model, billing insurance companies, healthcare providers, and patients for laboratory testing services. Go-to-market combines enterprise field sales targeting hospital systems and physician practices with hospital-lab joint venture partnerships (e.g., Baptist Memorial, NYU Langone, ProMedica) and direct distribution through 550+ patient service centers. The company is the third largest laboratory medicine company in the US, processing 80 million tests annually through a workforce of 7,500+ (including 380+ pathologists, 400+ fellowship-trained subspecialists, 2,000+ phlebotomists, and 650+ couriers), and operates under the Medical Leadership philosophy where pathologists lead from board-level through operational roles.

Name

Aurora Diagnostics Holdings, LLC

Legal name

Aurora Diagnostics Holdings, LLC

Website

https://auroradx.com

Company type

Private

Founded year

2006

Operating status

Acquired

Short description

Aurora Diagnostics Holdings, LLC, founded in 2006 and acquired by Sonic Healthcare USA in 2019, operates as the Sonic Healthcare USA Anatomic Pathology Division, providing anatomic pathology, molecular diagnostics, dermatopathology, and companion diagnostic testing services through 380+ pathologists, 550+ patient service centers, and hospital-lab joint ventures across the United States.

Ownership category

akta.pro rank

Product category

Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB), Dermatopathology (HLAKACAC), Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)

Keywords

• Anatomic pathology services
• Molecular diagnostic testing
• Dermatopathology services
• Companion diagnostics
• Clinical laboratory services

Headquarters

HQ city

Palm Beach Gardens

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Laboratory Services: Revenue generated from diagnostic laboratory testing services including anatomic pathology, molecular diagnostics, dermatopathology, hospital services, and specialized testing. Services are billed to patients, insurance companies, and healthcare providers.
2. Reference Laboratory Testing: Specialized esoteric testing performed at Sonic Reference Laboratory and other specialized facilities, providing complex diagnostic testing to other laboratories and healthcare providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Aurora Diagnostics Holdings, LLC, operating as the Sonic Healthcare USA Anatomic Pathology Division, provides anatomic pathology and clinical diagnostic laboratory services through a national network of 380+ fellowship-trained pathologists across the United States. The company delivers molecular diagnostics, dermatopathology, hospital pathology services, oncology companion diagnostics, women's health testing, and infectious disease testing, processing approximately 80 million tests annually and serving millions of patients through 550+ patient service centers.

Product overview

Aurora Diagnostics Holdings, LLC (operating as Sonic Healthcare USA's Anatomic Pathology Division) offers a comprehensive diagnostic testing portfolio centered around molecular diagnostics and anatomic pathology services. The core offering includes specialized testing across oncology (ThyroSeq, AuraSeq NGS panels, Companion Diagnostics including FOLR1, MMR RxDx, and PD-L1), women's health (AVID Complete, AVID Screen, AVID Auto-Reflex), COVID-19/flu multiplex testing, dermatopathology, and hospital services. The portfolio is unified through integrated technology platforms including PathologyWatch with 'dot.' AI-powered digital pathology, iMorpheus clinical decision support informatics, and SonicMyAccess patient portal. Testing is delivered through a network of 380+ pathologists across the United States.

Differentiator

Problem solved

Functional benefit

Brands

• AVID Complete: AVID Complete is a test engineered specifically for identifying trichomoniasis, candida vaginitis (CV), and bacterial vaginosis (BV).
• AVID Screen
• AVID Auto-Reflex
• AuraSeq
• ThyroSeq
• FOLR1 (FOLR1-2.1)
• MMR RxDx Panel

Products and services

• Anatomic Pathology Services Comprehensive diagnostic anatomic pathology services delivered through a network of 380+ pathologists across the United States, serving hospitals, health systems, and physician practices.
• Dermatopathology Services Specialized dermatopathology diagnostic services for skin conditions including melanoma, squamous cell carcinoma, and basal cell carcinoma, supported by the PathologyWatch digital pathology platform.
• Molecular Diagnostics Services Molecular pathology testing using next-generation sequencing technology for cancer biomarker assessment and genomic profiling, supporting oncology and personalized medicine.
• Hospital Services Comprehensive pathology and laboratory services supporting hospital laboratory and diagnostic operations, including joint venture and partnership models with health systems.
• ThyroSeq Thyroid cancer molecular testing solution using next-generation sequencing technology to enable precise diagnosis and treatment decisions for thyroid nodules and cancer.
• AVID Complete Women's health test engineered specifically for identifying trichomoniasis, candida vaginitis (CV), and bacterial vaginosis (BV) through a single molecular assay.
• AVID Screen Comprehensive molecular testing for bacterial vaginosis as part of the AVID women's health diagnostics suite.
• AVID Auto-Reflex Women's health testing with automated reflex protocols providing personalized and quality care for patients based on initial screening results.
• AuraSeq Comprehensive Panel Highly multiplexed next-generation sequencing assay identifying clinically relevant alterations in 500 cancer-related genes, including base pair substitutions, insertions and deletions in mutational hotspots, copy number variations, intergenic and intragenic fusions, and genomic signatures.
• FOLR1 (FOLR1-2.1) First FDA-approved immunohistochemistry companion diagnostic test that detects the Folate Receptor (FOLR1) biomarker in patients with epithelial ovarian cancer, identifying patients eligible for FR alpha-targeted therapy.
• MMR RxDx Panel First FDA-approved immunohistochemical companion diagnostic test to identify endometrial cancer patients eligible for anti-PD1 immunotherapy with JEMPERLI (dostarlimab-gxly).
• PD-L1 Testing FDA-approved indication-specific PD-L1 immunohistochemistry stains for melanoma, bladder, lung, breast, gastro-esophageal, cervical, and head and neck cancers, supporting immunotherapy selection.
• COVID-19 Testing Comprehensive COVID-19 testing solutions including NAAT (PCR), COVID-19/Flu Multiplex NAAT, Rapid COVID-19 Antigen, and COVID-19 Antibody testing developed under the guidance of a COVID-19 Task Force.
• PathologyWatch with 'dot.' Technology Integrated end-to-end digital pathology platform for skin pathology featuring laboratory information system, digital pathology viewer, image storage, and AI algorithms powered by 'dot.' (dermatopathology optimization tool) technology for AI-assisted dermatopathology case analysis.

Quantifiable outcome

• Streamline lab operations reducing labor costs by 10-15%
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CellCartacoreStrategic or Co-development Partner · 1 June 2026Collaboration to expand access to companion diagnostic testing and strengthen clinical trial support across the United States. Combines Sonic Healthcare USA's clinical laboratory network with CellCarta's companion diagnostic assay development and regulatory expertise. Expected to support oncology and autoimmune disease programs.
• Cairo Diagnostics LLCcoreStrategic or Co-development Partner · 1 August 2025Acquisition of Cairo Diagnostics, a respected provider of comprehensive hematology oncology diagnostics based in White Plains, NY with second laboratory in Woodcliff Lake, NJ. Cairo provides integrated oncology testing combining histopathology, molecular diagnostics, cytogenetics, flow cytometry, and immunohistochemistry.
• PathologyWatchcoreStrategic or Co-development Partner · 1 March 2024Acquisition of PathologyWatch, an innovative medical technology practice headquartered in Salt Lake City, UT with additional labs in Phoenix, AZ and Port Charlotte, FL. PathologyWatch has developed an integrated end-to-end digital pathology platform for skin pathology powered by 'dot.' (dermatopathology optimization tool) AI technology.
• ProMedica Health SystemcoreStrategic or Co-development Partner · 1 August 2018Joint venture between Sonic Healthcare USA and ProMedica Health System to enhance laboratory services. This partnership demonstrates the company's hospital-lab partnership model for integrated diagnostic services.
• NYU Langone DiagnosticscoreStrategic or Co-development Partner · 1 January 2017Strategic partnership with NYU Langone to form joint venture NYU Langone Diagnostics, aimed at growing NYU outreach and laboratory business.
• Constitution Diagnostics NetworkminorStrategic or Co-development Partner · 1 January 2017Joint venture with Western Connecticut Health Network to provide enhanced laboratory services throughout Connecticut.
• Baptist Memorial Health SystemcoreStrategic or Co-development PartnerStrategic partnership with Baptist Memorial Health System establishing American Esoteric Laboratories flagship regional core laboratory in Memphis, TN featuring BD total microbiology automation. Collaboration created fully integrated 24/7 service model.
• Proteomics InternationalminorOEM/ Whitelabel/ Licensing PartnerExclusive license agreement for commercialization of PromarkerD test for diabetic kidney disease in the United States market.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mayo Clinic Laboratories: Hospital-affiliated reference laboratory of Mayo Clinic offering broad esoteric and anatomic pathology testing — directly comparable in test menu breadth, hospital-system partnership model, and clinical leadership positioning.
• ARUP Laboratories: Major US reference laboratory specializing in esoteric and anatomic pathology, affiliated with the University of Utah; closely comparable as a pathologist-led, subspecialty-focused reference lab serving hospitals and health systems.
• BioReference Laboratories: Full-service clinical laboratory offering routine, esoteric, and molecular diagnostics with a national footprint and significant oncology/urology testing depth — a direct competitor for hospital outreach and specialty physician lab work.
• NeoGenomics: Oncology-focused clinical laboratory providing molecular and anatomic pathology services with broad NGS and hematopathology offerings — directly comparable in oncology companion diagnostics, hematopathology, and hospital outreach lab services.

Emerging players

• Tempus AI: AI-driven precision medicine company offering NGS testing, clinical decision support, and digital pathology AI — overlaps with the iMorpheus informatics platform and 'dot.' AI dermatopathology capabilities, representing a tech-forward emerging competitor.
• Foundation Medicine: Molecular information company providing comprehensive genomic profiling assays for solid tumors and hematologic malignancies — comparable to AuraSeq in comprehensive NGS-based companion diagnostic testing for oncology treatment selection.
• Guardant Health: Specialized molecular diagnostics company focused on liquid biopsy and NGS-based oncology testing — emerging peer whose technology overlaps with the AuraSeq NGS portfolio for oncology biomarker profiling.

Broad incumbents

• Quest Diagnostics: Largest US clinical laboratory company with a nationwide patient service center network, broad test menu, and anatomic pathology capabilities — directly comparable as the dominant incumbent against whom SHUSA AP Division competes for hospital and physician lab contracts.
• Laboratory Corporation of America (LabCorp): Second-largest US clinical laboratory network with national footprint in routine and esoteric testing, including anatomic pathology — a direct broad incumbent competitor for hospital lab outsourcing and commercial payer contracts.

Others

• Sonic Healthcare Limited: Australian parent company of Sonic Healthcare USA and the operating entity that owns the Aurora Diagnostics / Anatomic Pathology Division — relevant as the strategic acquirer and capital backer behind the US pathology franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sonic-healthcare-usa/?viewAsMember=true

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Diagnostics Holdings, LLC